_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
_256_384.jpg)
Visby Medical’s instrument-free PCR test to detect the SARS-CoV-2 virus can now be used to pool up to five patient samples using a single test
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
Research collaboration covers multiple antibody research programs
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
This clinical study demonstrated that the 14-day regimen of ImmunoSEB and ProbioSEB CSC3 resolved post-Covid-19 fatigue symptoms and improved patients' functional status and quality of life
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
Extension of hypericin orphan designation beyond cutaneous T-cell lymphoma
Subscribe To Our Newsletter & Stay Updated
